Blood direct PCR: impact of CYP2C19 and CYP4F2 variants for bleeding prediction in ST-elevation myocardial infarction patients with ticagrelor.

IF 1.7 4区医学 Q3 PHARMACOLOGY & PHARMACY

Personalized medicine Pub Date : 2022-05-01 Epub Date: 2022-02-17 DOI:10.2217/pme-2021-0152

Vacis Tatarunas, Ali Aldujeli, Zemyna Kurnickaite, Laurynas Maciulevicius, Marius Burkanas, Jonas Venius, Ieva Ciapiene, Vilius Skipskis, Rita Norvilaite, Agne Giedraitiene, Ramunas Unikas, Giedre Baksyte, Olivija Gustiene, Gintare Sakalyte, Vaiva Lesauskaite

{"title":"Blood direct PCR: impact of CYP2C19 and CYP4F2 variants for bleeding prediction in ST-elevation myocardial infarction patients with ticagrelor.","authors":"Vacis Tatarunas, Ali Aldujeli, Zemyna Kurnickaite, Laurynas Maciulevicius, Marius Burkanas, Jonas Venius, Ieva Ciapiene, Vilius Skipskis, Rita Norvilaite, Agne Giedraitiene, Ramunas Unikas, Giedre Baksyte, Olivija Gustiene, Gintare Sakalyte, Vaiva Lesauskaite","doi":"10.2217/pme-2021-0152","DOIUrl":null,"url":null,"abstract":"Aims: The goals of this study were to develop a new technique that could pave the way for a quicker determination of CYP4F2 rs3093135 and CYP2C19 rs4244285 variants directly from a patient's blood and to attempt to apply this technique in clinical practice. Patients & methods: The study included 144 consecutive patients admitted with ST elevation myocardial infarction. A blood-direct PCR and real-time PCR were used to detect variants of interest. Results & conclusion: Patients with bleeding events had the CYP2C19 GG (*1*1) variant more frequently than patients without bleeding events. The CYP4F2 TT variant was more frequently detected in patients with bleeding events 3 months after hospitalization.","PeriodicalId":19753,"journal":{"name":"Personalized medicine","volume":"19 3","pages":"207-217"},"PeriodicalIF":1.7000,"publicationDate":"2022-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Personalized medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2217/pme-2021-0152","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/2/17 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 1

Abstract

Aims: The goals of this study were to develop a new technique that could pave the way for a quicker determination of CYP4F2 rs3093135 and CYP2C19 rs4244285 variants directly from a patient's blood and to attempt to apply this technique in clinical practice. Patients & methods: The study included 144 consecutive patients admitted with ST elevation myocardial infarction. A blood-direct PCR and real-time PCR were used to detect variants of interest. Results & conclusion: Patients with bleeding events had the CYP2C19 GG (*1*1) variant more frequently than patients without bleeding events. The CYP4F2 TT variant was more frequently detected in patients with bleeding events 3 months after hospitalization.

查看原文本刊更多论文

血液直接PCR: CYP2C19和CYP4F2变异对替格瑞洛st段抬高型心肌梗死患者出血预测的影响

目的:本研究的目的是开发一种新技术，为直接从患者血液中更快地测定CYP4F2 rs3093135和CYP2C19 rs4244285变异铺平道路，并尝试将该技术应用于临床实践。患者与方法:研究纳入144例ST段抬高型心肌梗死患者。采用血液直接PCR和实时PCR检测感兴趣的变异。结果与结论:有出血事件的患者CYP2C19 GG(*1*1)变异发生率高于无出血事件的患者。CYP4F2 TT变异更常见于住院后3个月出血事件的患者。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Personalized medicine 医学-药学

CiteScore

3.30

自引率

4.30%

发文量

审稿时长

6-12 weeks

期刊介绍： Personalized Medicine (ISSN 1741-0541) translates recent genomic, genetic and proteomic advances into the clinical context. The journal provides an integrated forum for all players involved - academic and clinical researchers, pharmaceutical companies, regulatory authorities, healthcare management organizations, patient organizations and others in the healthcare community. Personalized Medicine assists these parties to shape thefuture of medicine by providing a platform for expert commentary and analysis. The journal addresses scientific, commercial and policy issues in the field of precision medicine and includes news and views, current awareness regarding new biomarkers, concise commentary and analysis, reports from the conference circuit and full review articles.